CTOs on the Move

Genoa Pharmaceuticals Inc

www.genoapharma.com

 
Genoa is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. With offices in Seattle and San Diego, Genoa`s experienced clinical and inhaled product development team is rapidly advancing Aerodone for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Genoa Pharmaceuticals Inc raised $62M on 05/15/2017

Similar Companies

ArsenalBio

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Its discovery engine comprises non-viral manufacturing based on its CellFoundry™ technology, integrated circuits incorporating its PrimeR™ logic gates and CAR enhancements from its CARchitecture™ library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.

Styker Biotech

Styker Biotech is a West Lebanon, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intracel Resources

Intracel Resources is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.

Fraunhofer Center for Molecular Biology

Fraunhofer Center for Molecular Biology is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.